Literature DB >> 20823145

"Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair.

Norman Chan1, Robert G Bristow.   

Abstract

Hypoxia exists in every solid tumor and is associated with poor prognosis because of both local and systemic therapeutic resistance. Recent studies have focused on the interaction between tumor cell genetics and the dynamic state of oxygenation and metabolism. Hypoxia generates aggressive tumor cell phenotypes in part owing to ongoing genetic instability and a "mutator" phenotype. The latter may be due to suppression of DNA mismatch repair (MMR), nucleotide excision repair (NER), and double-strand break (DSB) repair. We propose a theoretical model in which hypoxia-mediated defects in DNA repair can lead to "contextual loss of heterozygosity" and drive oncogenesis. Additionally, hypoxia-mediated repair defects can be specifically targeted by DNA damaging agents and/or "contextual synthetic lethality" to kill repair-deficient cells and preserve the therapeutic ratio. These proposed concepts support the interrogation of solid tumors to document repair defects in both oxic and hypoxic tumor subregions as a conduit to novel clinical trials within the context of personalized medicine. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20823145     DOI: 10.1158/1078-0432.CCR-10-0527

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer: author reply.

Authors:  A Berlin; A Dal Pra; R G Bristow
Journal:  Br J Radiol       Date:  2015-01       Impact factor: 3.039

2.  EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork-Associated DNA Damage Repair.

Authors:  Mohammad Saki; Haruhiko Makino; Prashanthi Javvadi; Nozomi Tomimatsu; Liang-Hao Ding; Jennifer E Clark; Elaine Gavin; Kenichi Takeda; Joel Andrews; Debabrata Saha; Michael D Story; Sandeep Burma; Chaitanya S Nirodi
Journal:  Mol Cancer Res       Date:  2017-08-11       Impact factor: 5.852

Review 3.  Repair of oxidatively induced DNA damage by DNA glycosylases: Mechanisms of action, substrate specificities and excision kinetics.

Authors:  Miral Dizdaroglu; Erdem Coskun; Pawel Jaruga
Journal:  Mutat Res Rev Mutat Res       Date:  2017-02-16       Impact factor: 5.657

Review 4.  Pharmacotherapeutic management of locally advanced prostate cancer: current status.

Authors:  Jarad M Martin; Stephane Supiot; Dominik R Berthold
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

5.  Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

Authors:  Paola Neri; Li Ren; Kathy Gratton; Erin Stebner; Jordan Johnson; Alexander Klimowicz; Peter Duggan; Pierfrancesco Tassone; Adnan Mansoor; Douglas A Stewart; Sagar Lonial; Lawrence H Boise; Nizar J Bahlis
Journal:  Blood       Date:  2011-09-13       Impact factor: 22.113

Review 6.  Molecular radiobiology: the state of the art.

Authors:  Amato J Giaccia
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 7.  Modulation of the tumor vasculature and oxygenation to improve therapy.

Authors:  Dietmar W Siemann; Michael R Horsman
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

8.  Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells.

Authors:  E Dickreuter; I Eke; M Krause; K Borgmann; M A van Vugt; N Cordes
Journal:  Oncogene       Date:  2015-06-15       Impact factor: 9.867

Review 9.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

10.  Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.

Authors:  Mackenzie Coatham; Xiaodong Li; Anthony N Karnezis; Lien N Hoang; Basile Tessier-Cloutier; Bo Meng; Robert A Soslow; C Blake Gilks; David G Huntsman; Colin J R Stewart; Lynne M Postovit; Martin Köbel; Cheng-Han Lee
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.